Artikel
The Abiraterone-Withdrawal-Syndrome. Rare phenomenon and/or therapeutic tool in therapy of advanced prostate cancer
Suche in Medline nach
Autoren
Veröffentlicht: | 8. April 2019 |
---|
Gliederung
Text
Background: Prostate cancer is the most frequently diagnosed malignancy and the second leading cause of cancer specific death in aging male in the western world.
The androgen deprivation therapy remains the standard of care for men with advanced prostate cancer. While the withdrawal-syndrome is well reported for all primary antiandrogens, it is a rarity in the therapy with Abiraterone.
Material, methods, results: We report about two patients from our day-to-day praxis with a significant Abiraterone (AA) withdrawal syndrome and a PSA decrease of more than 80% and more than 50% respectively after cessation of AA and discuss the available literature respecting molecular mechanism and therapeutic consequences.
Conclusion: The definite mechanism remains unclear. Nevertheless, the syndrome arises at a low percentage of patients. If this circumstance is kept in mind and recognized at an early stage, it could possibly be used as a therapeutic tool in tumour therapy.